Mauro Piacentini
Prof. Mauro Piacentini is Professor Emeritus of Cell and Developmental Biology at the University of Rome “Tor Vergata” since 2024. He also served there as Full Professor (2000–2003), as an elected member of the Board of Directors (2013–2021), and as President of the Degree Program in Biotechnology (2005–2013). Since 1998, he has been the Director of the Laboratory of Cell Biology and Electron Microscopy at the National Institute for Infectious Diseases IRCCS “Lazzaro Spallanzani”. From 2018 to 2025, he served as President of the Technical Health Committee of the Italian Ministry of Health. Since 2006 is Scientific Director of Heal Italia Foundation. He is actively involved in numerous...
Mauro Piacentini
Mini BioProf. Mauro Piacentini is Professor Emeritus of Cell and Developmental Biology at the University of Rome “Tor Vergata” since 2024. He also served there as Full Professor (2000–2003), as an elected member of the Board of Directors (2013–2021), and as President of the Degree Program in Biotechnology (2005–2013). Since 1998, he has been the Director of the Laboratory of Cell Biology and Electron Microscopy at the National Institute for Infectious Diseases IRCCS “Lazzaro Spallanzani”. From 2018 to 2025, he served as President of the Technical Health Committee of the Italian Ministry of Health. Since 2006 is Scientific Director of Heal Italia Foundation. He is actively involved in numerous scientific and educational collaborations with prominent international institutions (Karolinska Institute in Sweden, Gustave Roussy Institute and Paris Cite University in France, Newcastle University in the UK, Russian Academy of Sciences, Federal University of São Paulo in Brazil, and Debrecen University in Hungary). He was President of the European Cell Death Organization (2002–2005). His many successful international collaborations earned him, among other honors, the prestigious European “Descartes Award” for collaborative research in 2007. He is one of the founders and senior editors of the journal Cell Death and Differentiation (IF 13.6) and Editor-in-Chief of Cell Death and Disease (IF 12.4), both published by Springer/Nature. His scientific output includes approximately 400 peer-reviewed articles (H-index: 90 on Scopus, 107 on Google Scholar, and over 65,000 citations), published in leading international journals (Nature, Science, Nature Medicine, Nature Cell Biology, Journal of Experimental Medicine, PNAS, etc.). He has delivered numerous invited scientific lectures at major national and international conferences (Gordon Conference, Nobel Conference, Philippe Laudat Conference, ECDO Conference, among others). His scientific interests have focused on the study of molecular mechanisms regulating cell death and autophagy, and their role in the pathogenesis of cancer (Head and Neck, Hepatocellular Carcinoma, Melanoma, Neuroblastoma) and infectious diseases (HIV, HCV, MTB). He has received numerous national (AIRC, Telethon, Ministry of Health, Ministry of University, CNR, Istituto Superiore di Sanità, Lazio Region, Cystic Fibrosis Foundation) and international grants (9 European projects and a Mega-Grant from the Russian Academy of Sciences), totaling over 10 million euros.
Scientific Publishing in the Era of Artificial Intelligence
The rapid development of artificial intelligence (AI), particularly large language models (LLMs) and generative AI, is profoundly transforming the landscape of scientific publishing. AI is reshaping every stage of the publication process, from literature discovery and hypothesis generation to manuscript drafting, language editing, peer review, and post-publication analysis. These technologies have the potential to increase productivity, improve accessibility for non-native English speakers, accelerate knowledge dissemination, and facilitate the synthesis of rapidly expanding scientific literature. At the same time, the widespread adoption of AI raises important concerns regarding scientific integrity, authorship, transparency, reproducibility, plagiarism, fabricated data and references, algorithmic bias, and the potential amplification of misinformation. Publishers, editors, reviewers, and research institutions are therefore challenged to establish clear ethical frameworks and robust guidelines governing the responsible use of AI throughout the scientific workflow. Rather than replacing human expertise, AI should be viewed as an assistive technology that complements critical thinking, scientific creativity, and ethical judgment, while preserving human accountability for the accuracy and originality of published research. Future scientific publishing will likely evolve toward a hybrid model in which AI supports routine and analytical tasks, whereas human researchers maintain responsibility for hypothesis generation, experimental design, interpretation of results, and final editorial decisions. Ensuring transparency in AI-assisted writing, developing reliable AI-detection and validation tools, and promoting international standards for responsible AI use will be essential to maintain trust in scientific literature. Ultimately, the integration of AI into scholarly communication represents both an unprecedented opportunity to accelerate scientific discovery and a critical test of the research community's ability to preserve the principles of rigor, reproducibility, and integrity that underpin scientific progress.